Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

R. Glen Wiggans, Paul V. Woolley, John S. Macdonald, Tarilyn Smythe, Winston Ueno, Philip S. Schein

Research output: Contribution to journalArticle

87 Scopus citations


Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
Issue number2
StatePublished - Feb 1978


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this